Safety and Efficacy Study of 225Ac-DOTA-IBA in the Treatment of Bone Metastases
This study indicated that 225Ac-DOTA-IBA was a promising and well-tolerated therapeutic for bone metastases, demonstrating acceptable toxicity and notable efficacy, including 177Lu-DOTA-IBA-refractory cases. Subgroup analyses indicated that patients with bone-only metastases derived particular clinical benefit.
Authors
- Naiguo Xing
- Hongyi Liu (ORCID: https://orcid.org/0000-0003-0086-4813)
- Ke Cheng
- Yueqi Zhao
- Xinyue Guo
- Xiaoyan Shang
- Wei Wang
- Yue Chen
Institutions
- Southwest Medical University (CN)
- Affiliated Hospital of Southwest Medical University (CN)
- Theranostics (New Zealand) (NZ)
- Molecular Theranostics (United States) (US)
Publication Details
- Journal
- Clinical Nuclear Medicine
- Published
- 2026-03-02
- DOI
- https://doi.org/10.1097/rlu.0000000000006333
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00